ACHN Achillion Pharmaceuticals Inc.

Achillion to Present at the Baird 2019 Global Healthcare Conference

Achillion to Present at the Baird 2019 Global Healthcare Conference

BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the Baird 2019 Global Healthcare Conference on Thursday, September 5, 2019, at 12:50 p.m. ET at the InterContinental New York Barclay in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentation will be accessible from the Company's investor relations website, . The audio recording will be archived for 60 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a clinical-stage biopharmaceutical company focused on advancing its oral small molecule complement inhibitors into late-stage development and commercialization. Research has shown that an overactive complement system plays a critical role in multiple disease conditions including the therapeutic areas of nephrology, hematology, ophthalmology and neurology. Achillion is initially focusing its drug development activities on complement-mediated diseases where there are no approved therapies or where existing therapies are inadequate for patients. Potential indications being evaluated for its compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN). Each of the product candidates in the Company’s oral small molecule portfolio was discovered in its laboratories and is wholly owned. To advance its investigational product candidates into Phase 3 clinical trials and commercialization, the Company plans to work closely with key stakeholders including healthcare professionals, patients, regulators and payors.

Investor Relations:

A. Clayton Robertson

Achillion Pharmaceuticals, Inc.

Tel. (215) 709-3078

Media:

Susanne Heinzinger

Senior VP, Corporate Communications

Achillion Pharmaceuticals, Inc.

Tel. (215)709-3032

 

EN
29/08/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Achillion Pharmaceuticals Inc.

 PRESS RELEASE

Achillion Shareholders Approve Agreement to be Acquired by Alexion

Achillion Shareholders Approve Agreement to be Acquired by Alexion BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period un...

 PRESS RELEASE

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4...

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting – 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 - BLUE BELL, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) --  Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company de...

Increased risk weighs on ACHILLION PHARMS.INCO., penalising its ratin...

The independent financial analyst theScreener just lowered the general evaluation of ACHILLION PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date December 6, 2019, the c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch